is unaffected by the recommendation GSK also has a five-in-one meningococcal vaccine candidate, which combines the antigenic components of Menveo and its approved meningococcal group B vaccine Bexsero ...

meningitidis, designed to protect against meningitis – including GSK’s MenB shot Bexsero – may also offer partial protection against gonorrhoea. An investigator-led study reported at the ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.50. The company’s shares closed yesterday at p1,497. ...

Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £18.00. The company’s shares closed yesterday at p1,497. ...

As part of the agreement, GSK, Sanofi, and CSL will produce extra bulk vaccine components tailored to the circulating strains of avian influenza. Also Read: Medicare Drug Price Negotiation Program ...

GlaxoSmithKline Pharmaceuticals Ltd. engages in the business of manufacturing, distributing and trading in pharmaceuticals. The company's product portfolio includes prescription medicines and ...

GSK and iTeos anti-TIGIT antibody belrestotug showed efficacy in a phase 2 trial in PD-L1-positive non-small cell lung cancer (NSCLC), providing some much-needed positive news for the beleaguered ...

Teva Pharmaceutical Industries Ltd. ADR-0.76% $19.75B ...

Copyright © 2024 MarketWatch, Inc. All rights reserved.

GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Service Income and Other Operating Revenue for the year ending 31-Mar-2024.For the quarter ended 30-06-2024, ...

Quant Mid Cap Fund - Direct (G) 228.24 8,29,800 2.40 Quant Large and Mid Cap Fund - Direct (B) 62.16 2,26,000 1.62 Quant Large and Mid Cap Fund - Direct (IDCW) 62.16 2,26,000 1.62 Quant Large and Mid ...